Diligence memo · auto-generated · as of July 2, 2026

Biolase, Inc

Biolase, Inc looks under-valued against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Biolase, Inc operates in Other Health Care, based in Lake Forest.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Biolase, Inc has raised $23M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $9.0M on 2011-06-24.

Most recent recorded round closed around 2023-12-06.

Valuation (modeled)modeled

Provath models Biolase, Inc at approximately $16M (range $3.5M–$40M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.44× the median modeled value of Series A Other Health Care companies in 2022–2024 (196 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 50 months.

Last raise 2.6 yr ago; this sector typically re-raises about every 14 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round was 2.5× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 85% of Other Health Care peers (5377 compared).

Modeled value ranks above 44% of those peers.

Closest niche peers: CareHarmony, Inc., Dragonfly Endoscopy Inc., NuvoAir Holdings, Inc., Post Acute Recovery, Inc., Micro Interventional Devices, Inc..

Peoplefiled

22 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.